POLG and Alpers syndrome: Pathogenic mutations in POLG have been identified in patients with neurological or muscular diseases including progressive external ophthalmoplegia (PEO), Alpers syndrome, ataxia-neuropathy syndromes, idiopathic parkinsonism, and nucleoside reverse-transcriptase inhibitor (NRTI) toxicity [11], [12].